Company profile: Shoreline Biosciences
1.1 - Company Overview
Company description
- Provider of engineered cellular immunotherapies for seriously ill patients, leveraging an iPSC-based modular development system for gene editing to optimize therapeutic profiles. Offerings include iNK cells to target and eliminate cancer cells and iMACs to modify the tumor microenvironment and stimulate an anti-tumor immune response.
Products and services
- IMACs: Engineered macrophages intended to modify the tumor microenvironment and stimulate an anti-tumor immune response for seriously ill patients
- INK cells: Genetically engineered natural killer cells that target and eliminate cancer cells, featuring enhanced durability and activity
- IPSC Approach: Modular system for cellular immunotherapy development, enabling gene editing to optimize therapeutic profiles for seriously ill patients
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Shoreline Biosciences
Myelo Therapeutics
HQ: Germany
Website
- Description: Provider of treatments addressing high unmet medical needs, focused on developing myelo001, a small molecule effective on hematogenesis and investigated for its oral application in treating chemotherapy-induced myelosuppression, radiation-induced myelosuppression, and acute radiation syndrome. Founded in 2013 and based in Berlin, Germany.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Myelo Therapeutics company profile →
Imagion Biosystems
HQ: United States
Website
- Description: Provider of molecularly targeted magnetic nanoparticles (MagSense) for cancer detection, developing imaging agents for solid tumors to aid diagnosis and staging, and conducting a Phase 1 HER2 breast cancer lymph node study aiming to avoid biopsies. Offers PrecisionMRX nanoparticles for MRI, hyperthermia, and magnetic particle imaging; supplies SPIONs with multiple coatings and nanoparticles for third-party biomedical applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Imagion Biosystems company profile →
Cinfa Biotech
HQ: Spain
Website
- Description: Provider of biosimilars development and manufacturing exclusively in Europe, adhering to strict guidelines and highest European quality standards with specialist know-how. Founded in 2013 as part of the Spanish Cinfa Group; active in the global biosimilars market and currently has two products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cinfa Biotech company profile →
Onxeo
HQ: France
Website
- Description: Provider of oncology drug R&D and platforms, offering Beleodaq (belinostat), a histone deacetylase inhibitor marketed in the US for injection; Livatag, a nanoparticle doxorubicin in Phase III for primary liver cancer; and pipeline programs including platON, a decoy oligonucleotide platform for cancer and inflammatory diseases; AsiDNA, a DNA-repair decoy; and VIO-01, a pan‑DDR decoy activating STING.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onxeo company profile →
Notable
HQ: United States
Website
- Description: Provider of personalized drug combination testing for cancer patients and a Predictive Medicine Platform (PMP) that predicts patient response to specific therapies to identify responsive patients before treatment. Develops therapeutics, including Presponse Therapeutics and the PLK-1 inhibitor volasertib, with development guided by predictive patient response data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Notable company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Shoreline Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Shoreline Biosciences
2.2 - Growth funds investing in similar companies to Shoreline Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Shoreline Biosciences
4.2 - Public trading comparable groups for Shoreline Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →